1Anderson FA Jr, Wheeler HB, Goldberg RJ, et al.A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study.Arch Intern Med,1991,151:933-938.
3Urokinase Pulmonary embolism trial: a national cooperative study. Circulation ,1973, 47:1-108.
4Goldhaber SZ, Kessler CM, Heit J, et al.Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism.Lancet,1988,2:293-298.
5Goldhaber SZ. Evolving concepts in thrombolytic therapy for pulmonary embolism.Chest,1992,101(4 Suppl):183S-185S.
6Daniels LB, Parker JA, Patel SR, et al.Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism.Am J Cardiol, 1997,80:184-188.
7Arcasoy SM, Kreit JW.Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence.Chest,1999,115:1695-1707.
7Torbieki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acule Pulmonary Embolism of the European Sociely of Cardiology ( ESC ) [ J]. Eur Heart J,2008,29(18) :2276-2315.
8Kyrle PA, Eichinger S. Deep vein thrombosis [ J ]. Lancet, 2005, 365(65) :1163.
9Cbauhan MS. Kawamura A. Percutaneous rheolytic thrombectomy for large pulmonary embolism: a promising treatment option [J]. Catheter Cardiovasc lnterv, 2007, 70( 1 ) : 121-128.
